Acute Lymphoblastic Leukemia

Introduction And Epidemiology

• Constitutes most common childhood malignancy.
• Accounts for 75-80% of all pediatric leukemias.
• Peak incidence occurs between 2-5 years of age.
• Arises from clonal proliferation of lymphoid precursors (B-cell or T-cell lineage).
• Increased risk associated with
  • Down syndrome (15-20 fold increased risk)
  • Neurofibromatosis
  • Schwachman-Diamond syndrome
  • Bloom syndrome
  • Ataxia telangiectasia.

Clinical Manifestations

Diagnostic Evaluation

Genetics And Risk Stratification

Cytogenetic Abnormalities And Prognostic Implications

National Cancer Institute (NCI) Classification

Serves as primary clinical baseline for initial risk assignment.

• Standard Risk (SR): Age 1 to 10 years AND white blood cell (WBC) count <50,000/μL.
• High Risk (HR): Age $\ge$ 10 years OR initial WBC count $\ge$ 50,000/μL.

Minimal Residual Disease (MRD)

Single most powerful prognostic indicator.

• Measurement: Flow cytometry, polymerase chain reaction, or next-generation sequencing.
• Favorable Threshold: Day 29 bone marrow MRD <0.01%.
• Adverse Threshold: Persistence of MRD $\ge$ 0.01% at end of induction; mandates treatment intensification.

Prognostic Factors Profile

Advanced Risk Grouping

B-Cell Lineage

Incorporates NCI criteria, cytogenetics, and MRD.

• Low Risk: SR criteria, favorable cytogenetics, MRD <0.01%.
• Standard Risk: Sub-stratified into Favorable, Average, and High based on cytogenetics, CNS status, and day 29 MRD.
• High Risk: HR criteria or SR with adverse features (steroid pretreatment, specific cytogenetics).
• Very High Risk: End of consolidation MRD $\ge$ 0.01%.

T-Cell Lineage

Stratification distinct from B-ALL; heavily dependent on MRD response.

• Standard Risk: Day 29 marrow MRD <0.01%, no CNS/testicular disease.
• Intermediate Risk: Day 29 marrow MRD $\ge$ 0.01%, but end of consolidation MRD <0.1%.
• Very High Risk: End of consolidation MRD $\ge$ 0.1% or induction failure.

Management And Treatment Strategies

The management of Acute Lymphoblastic Leukemia (ALL) is a complex, risk-adapted process involving systemic chemotherapy, CNS-directed therapy, and supportive care. Below is the summary of strategies based on the current clinical protocols.

Management Strategies for ALL

General Supportive Care

• Tumor Lysis Syndrome (TLS) Prevention: Aggressive intravenous hydration (2-3 times maintenance). Administer Allopurinol (300 mg/m²/day) or Rasburicase (0.15-0.2 mg/kg/day IV) for high-risk patients (WBC >100,000/mm³). Monitor electrolytes meticulously.
• Infection Prophylaxis: Pneumocystis jirovecii prophylaxis (Trimethoprim-sulfamethoxazole) mandatory throughout therapy.
• Febrile Neutropenia Management: Prompt hospitalization. Immediate broad-spectrum intravenous antibiotics (covering pseudomonas). Add antifungals if fever persists beyond 3-5 days.
• Transfusion Support: Irradiated, leukoreduced, cytomegalovirus-safe packed red blood cells and platelets administered for severe anemia or thrombocytopenia.

Phases Of Systemic Chemotherapy

1. Remission Induction Therapy

• Objective: Eradicate leukemia from bone marrow, restoring normal hematopoiesis (<5% blasts, normal counts).
• Duration: 4 weeks.
• Efficacy: Induces remission in 95-98% of patients.
• Standard Risk Regimen (3-Drug):
  • Glucocorticoid: Dexamethasone (6 mg/m²/day PO) or Prednisone. Dexamethasone improves CNS penetration and event-free survival but increases osteonecrosis risk in older children.
  • Vincristine: 1.5 mg/m² IV weekly (Days 0, 7, 14, 21).
  • L-Asparaginase: Pegylated asparaginase (PEG-asp) 2500 units/m² IV (Day 4).
• High Risk Regimen (4-Drug):
  • Adds Anthracycline: Daunorubicin (25-30 mg/m² IV weekly) to the 3-drug backbone.
• CNS Therapy: Age-adjusted Intrathecal (IT) Methotrexate and/or Cytarabine administered on Day 1, 8, and 29.

2. Consolidation Therapy (CNS Preventive Therapy)

• Objective: Eradicate subclinical disease in sanctuary sites (CNS and testes) and prevent drug resistance.
• Duration: 4 to 8 weeks.
• Regimen (Standard Risk):
  • 6-Mercaptopurine (6-MP): 75 mg/m²/day PO for 28 days.
  • Vincristine: 1.5 mg/m² IV on Day 1.
  • Intrathecal Methotrexate: Administered on Days 1, 8, 15.
• High-Risk / T-cell Modifications: Utilizes intensive systemic therapy including high-dose Cytarabine, Cyclophosphamide, and PEG-asparaginase.
• Cranial Radiation Therapy (CRT): Eliminated for most patients to prevent neurocognitive late effects. Strictly reserved for patients with overt CNS3 disease at diagnosis (1800 cGy administered during later phases).

3. Interim Maintenance

• Objective: Maintain remission while allowing marrow recovery prior to delayed intensification.
• Duration: 8 weeks.
• Regimen Options:
  • Capizzi Methotrexate (CMTX): Escalating intravenous Methotrexate doses starting at 100 mg/m² without Leucovorin rescue. Improves survival in Standard Risk patients.
  • High-Dose Methotrexate (HDMTX): 5000 mg/m² IV over 24 hours followed by Leucovorin rescue. Significantly improves outcomes for High-Risk patients.
• Concurrent Medications: Vincristine pulses, IT Methotrexate.

4. Delayed Intensification

• Objective: Re-induction and re-consolidation to eliminate residual resistant leukemic clones. Crucial for preventing late relapse.
• Duration: 8 weeks.
• Regimen Details:
  • Part 1 (Re-induction): Dexamethasone (10 mg/m²/day), Vincristine (1.5 mg/m² IV weekly), Doxorubicin (25 mg/m² IV weekly), PEG-asparaginase (2500 units/m² IV).
  • Part 2 (Re-consolidation): Cyclophosphamide (1000 mg/m² IV), Cytarabine (75 mg/m²/day IV), 6-Thioguanine (60 mg/m²/day PO).
  • CNS Therapy: IT Methotrexate.

5. Maintenance (Continuation) Therapy

• Objective: Eradicate minimal residual cell burden (10⁹-10¹⁰ cells) to prevent relapse.
• Duration: Prolonged phase lasting up to 2-3 years from diagnosis.
• Standard Backbone:
  • 6-Mercaptopurine: 75 mg/m²/day PO administered continuously. Thiopurine methyltransferase (TPMT) genotyping required to adjust dosage and prevent profound myelosuppression.
  • Methotrexate: 20 mg/m²/dose PO administered weekly.
• Pulses: Dexamethasone (3 mg/m²/dose BID for 5 days) and Vincristine (1.5 mg/m² IV) administered every 4 to 12 weeks depending on specific protocol.
• CNS Therapy: IT Methotrexate every 12 weeks.
• Monitoring: Titrate 6-MP and MTX to maintain absolute neutrophil count between 1500-2000/μL.

Management Of Specific ALL Subtypes

Philadelphia Chromosome-Positive (Ph+) ALL

• Features t(9;22) BCR-ABL1 translocation; historically carried grave prognosis.
• Targeted Therapy: Tyrosine Kinase Inhibitors (TKI) seamlessly integrated into standard chemotherapy backbones.
• Agents: Imatinib or Dasatinib administered continuously.
• Outcomes: TKI integration has dramatically improved 3-year survival to 80%. Routine Hematopoietic Stem Cell Transplant (HSCT) in first remission no longer universally required unless response to TKI is poor.

Infant ALL

• Age <1 year; highly associated with KMT2A (MLL) translocations.
• Extremely aggressive biological behavior.
• Therapy: Exceedingly intensive regimens utilizing high-dose Cytarabine and high-dose Methotrexate.
• Transplantation: High-risk infants frequently require allogeneic HSCT in first remission.

Mature B-Cell ALL (Burkitt Leukemia)

• Biologically identical to Burkitt Lymphoma; features FAB L3 morphology.
• Therapy Paradigm: Short, highly intensive pulsed chemotherapy (e.g., FAB/LMB 96 protocol).
• Agents: High-dose Cyclophosphamide, Methotrexate, Cytarabine.
• Immunotherapy: Rituximab (anti-CD20 monoclonal antibody) drastically improves survival (90-95% EFS).
• Maintenance therapy is entirely omitted for mature B-cell ALL.

T-Cell ALL

• High risk for CNS relapse and induction failure.
• Therapy: Utilizes intensified consolidation featuring Nelarabine (T-cell specific purine nucleoside analog) (650 mg/m² IV for 5 days) and high-dose Cytarabine/Methotrexate.
• Prophylactic cranial radiation historically utilized, but modern intensive systemic/intrathecal therapies increasingly negate its requirement.

Management Of Relapsed And Refractory Disease

• 15-20% of patients experience relapse (bone marrow, CNS, or testes).
• Re-induction Protocols: UK ALL R3 or COG platforms utilize intensive combinations.
• Example Regimen (Triple Reinduction): Vincristine, Prednisone, PEG-asparaginase, Doxorubicin, Cyclophosphamide, Etoposide, Cytarabine.
• Prognosis: Determined by time to relapse (early vs. late) and site (medullary vs. extramedullary). Early bone marrow relapses carry dismal prognoses, requiring prompt HSCT.

Novel Targeted And Cellular Therapies (Refractory/Relapsed Settings) #recent

Revolutionizing salvage therapy for relapsed/refractory B-ALL.

• Blinatumomab: Bispecific T-cell engager (BiTE). Dual affinity for CD19 (on leukemic blasts) and CD3 (on cytotoxic T-cells), activating endogenous T-cells to lyse blasts.
• Inotuzumab Ozogamicin: Antibody-drug conjugate targeting CD22, delivering cytotoxic calicheamicin directly into blasts.
• Chimeric Antigen Receptor (CAR) T-Cell Therapy (Tisagenlecleucel):
  • Autologous T-cells genetically engineered ex vivo to express receptors targeting CD19 antigen.
  • Elicits profound, durable remissions in highly refractory patients.
  • Complication Management: High risk for Cytokine Release Syndrome (CRS). Requires meticulous monitoring; managed with Tocilizumab (Anti-IL-6 receptor antibody) and Corticosteroids.

Hematopoietic Stem Cell Transplantation (HSCT)

• Reserved for specific high-risk indications due to significant morbidity and mortality (graft-versus-host disease, severe infections, late effects).
• Absolute Indications (ALL):
  • Primary induction failure (failure to achieve remission by end of induction).
  • Early bone marrow relapse (<18-36 months from diagnosis).
  • Second or subsequent remissions.
  • Specific cytogenetic abnormalities failing initial targeted therapy (e.g., refractory Ph+ ALL, extremely poor-responding MLL-rearranged infant ALL, extreme hypodiploidy).
• Preparative Conditioning: Typically utilizes Total Body Irradiation (TBI) (1200-1350 cGy) paired with high-dose Cyclophosphamide or Etoposide to ablate marrow and provide immunosuppression.